

SUBSTANTIAL SHAREHOLDERS

So far as is known to our Directors, immediately after the [REDACTED] (subject to the Assumptions), the following persons are expected to have an interest and/or short positions in our Shares or underlying Shares of our Company which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who are, directly or indirectly, is entitled to exercise, or control the exercise of, 10% or more of the voting power at any meeting of our Company or any other member of our Group:

Name	Nature of interest	Shares held as of the Latest Practicable Date		Shares held immediately after the [REDACTED] (subject to the Assumptions)	
		Number of Shares ⁽¹⁾	Approximate percentage of interest in our Company	Number of Shares ⁽¹⁾	Approximate percentage of interest in our Company
LAV USD ⁽²⁾	Beneficial owner	119,897,651	22.93%	119,897,651	[REDACTED]%
Shanghai Liyi ⁽³⁾ . .	Beneficial owner	55,381,999	10.59%	55,381,999	[REDACTED]%
Dr. Ji Darren Xiaohui.	Beneficial owner	53,249,811	10.18%	53,249,811	[REDACTED]%
HH SPR-XVI Holdings Limited ⁽⁴⁾	Beneficial owner	49,728,827	9.51%	49,728,827	[REDACTED]%

Notes:

- (1) All interests stated are long positions.
- (2) Represents (i) 90,275,381 Shares held by LAV Epoch Limited; (ii) 21,118,869 Shares held by LAV Biosciences Fund V, L.P.; (iii) 5,668,934 Shares held by LAV Amaranth Limited; and (iv) 2,834,467 Shares held by LAV Azure Limited.

LAV Epoch Limited is a company with limited liability incorporated under the laws of the BVI and is wholly owned by LAV Biosciences Fund IV, L.P., a Cayman exempted limited partnership fund. The general partner of LAV Biosciences Fund IV, L.P. is LAV GP IV, L.P., whose general partner is LAV Corporate IV GP, Ltd., a Cayman exempted company wholly owned by Dr. SHI Yi. Therefore, under the SFO, each of LAV Biosciences Fund IV, L.P., LAV GP IV, L.P., LAV Corporate IV GP, Ltd. and Dr. SHI Yi is deemed to be interested in the Shares held by LAV Epoch Limited.

LAV Biosciences Fund V, L.P. is a Cayman exempted limited partnership fund. The general partner of LAV Biosciences Fund V, L.P. is LAV GP V, L.P., whose general partner is LAV Corporate V GP, Ltd., a Cayman exempted company wholly owned by Dr. SHI Yi. Therefore, under the SFO, each of LAV GP V, L.P., LAV Corporate V GP, Ltd. and Dr. SHI Yi is deemed to be interested in the Shares held by LAV Biosciences Fund V, L.P.

LAV Amaranth Limited is a company with limited liability incorporated under the laws of the BVI and is wholly owned by LAV Biosciences Fund III, L.P., a Cayman exempted limited partnership fund. The general partner of LAV Biosciences Fund III, L.P. is LAV GP III, L.P., whose general partner is LAV Corporate GP, Ltd., a Cayman exempted company wholly owned by Dr. SHI Yi. Therefore, under the SFO, each of LAV Biosciences Fund III, L.P., LAV GP III, L.P., LAV Corporate GP, Ltd. and Dr. SHI Yi is deemed to be interested in the Shares held by LAV Amaranth Limited.

LAV Azure Limited is a company with limited liability incorporated under the laws of the BVI and is wholly owned by Lilly Asia Ventures Fund III, L.P., a Cayman exempted limited partnership fund. The general partner of Lilly Asia Ventures Fund III, L.P. is LAV GP III, L.P., whose general partner is LAV Corporate GP, Ltd., a Cayman exempted company wholly owned by Dr. SHI Yi. As of the Latest Practicable Date, Eli Lilly and Company, whose shares are listed on the New York Stock Exchange (ticker symbol: LLY), was a limited partner holding more than one-third of interest in Lilly Asia Ventures Fund III, L.P. Therefore, under the SFO, each of Lilly Asia Ventures Fund III, L.P., LAV GP III, L.P., LAV Corporate GP, Ltd., Eli Lilly and Company and Dr. SHI Yi is deemed to be interested in the Shares held by LAV Azure Limited. For details of LAV USD, see “History and Corporate Structure — Information Regarding the Pre-[REDACTED] Investors.”

- (3) Shanghai Liyi is a limited partnership established under the laws of the PRC. The general partner of Shanghai Liyi is Shanghai Liyi Investment Management Partnership (Limited Partnership) (上海禮頤投資管理合夥企業(有限合夥)), whose general partner is Shanghai Liyao Investment Management Co., Ltd. (上海禮曜投資管理有限公司), which is in turn wholly owned by Dr. CHEN Fei. Therefore, under the SFO, Shanghai Liyi Investment Management Partnership (Limited Partnership) (上海禮頤投資管理合夥企業(有限合夥)), Shanghai

SUBSTANTIAL SHAREHOLDERS

Liyao Investment Management Co., Ltd. (上海禮曜投資管理有限公司) and Dr. CHEN Fei is deemed to be interested in the Shares held by Shanghai Liyi. For details of Shanghai Liyi, see “History and Corporate Structure — Information Regarding the Pre-[REDACTED] Investors.”

- (4) HH SPR-XVI Holdings Limited is an exempted company with limited liability incorporated under the laws of the Cayman Islands and is wholly owned by Hillhouse Fund IV, L.P. Hillhouse Fund IV, L.P. is ultimately controlled by Hillhouse Investment Management, Ltd. Therefore, under the SFO, each of Hillhouse Fund IV, L.P. and Hillhouse Investment Management, Ltd. is deemed to be interested in the Shares held by HH SPR-XVI Holdings Limited. For details of Hillhouse Investment Management, Ltd., see “History and Corporate Structure — Information Regarding the Pre-[REDACTED] Investors.”

Except as disclosed above, our Directors are not aware of any persons who will, immediately following completion of the [REDACTED] (subject to the Assumptions), have any interests and/or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, is entitled to exercise, or control the exercise of, 10% or more of the voting power at any meeting of our Company or any other member of our Group.